EZH2 and breast cancer: This study found a new mechanism to regulate coordination between epigenetics (histone and miRNA) modification and glucose metabolism, which contribute to the progress and Adriamycin resistance of breast cancer, and demonstrated that the HDAC2/EZH2/miR-148a/PDK1 axis mediates breast cancer development and therapeutic resistance.